Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671089 | 0.90 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL14671078 | 0.86 | MEN1 (0.37) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL25009341 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10HRH3ALDH1A1CYP1A2 | |
| SCHEMBL15987022 | 0.82 | MEN1 (0.37) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL14671004 | 0.82 | OPRM1 (0.33) | GAAHRH3OPRL1OPRM1 | |
| SCHEMBL15984372 | 0.81 | OPRL1 (0.36) | HRH3ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14670918 | 0.78 | CYP2C9 (0.48) | HSD17B10ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16375282 | 0.77 | JAK3 (0.35) | KMT2AHRH3 | |
| SCHEMBL15987001 | 0.76 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL12125453 | 0.76 | KMT2A (0.56) | MEN1KMT2ASMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| WO-2013013308-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | MEN1 505/4885KMT2A 1111/4885SMN1; SMN2 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.